What Leanbio does

Leanbio S.L. is a Barcelona-based contract development and manufacturing organization (CDMO) founded in 2014 that provides end-to-end biologics services for biopharmaceutical companies and biotech startups. The company operates across five technological platforms — mammalian expression (CHO, HEK cells at scales from 3L to 2,000L), microbial expression (E. coli, Pichia pastoris, Bacillus subtilis, Saccharomyces cerevisiae at scales from 3L to 1,000L), plasmid DNA manufacturing, mRNA production via in vitro transcription, and bioconjugates including ADCs and PDCs — supported by an integrated service stack spanning tech transfer, cell line development, process development using Design of Experiments (DoE), analytical development, preclinical manufacturing, GMP cell banking, process validation, and cGMP manufacturing compliant with EMA and FDA standards. The company applies "lean thinking" methodologies to bioprocess design, with stated outcomes of faster timelines, lower costs, and high-titer cell lines for complex modalities including bispecific antibodies, fusion proteins, and ADCs.

Leanbio generates revenue through project-based CDMO engagements with milestone-driven payment structures across the development and manufacturing lifecycle. Pricing is quote-based and project-specific, determined by molecule, expression system, scale, and regulatory requirements rather than published rate cards. The go-to-market is enterprise-focused, combining direct sales outreach, industry conference participation (World ADC, Bioprocessing Summit Europe, CPhI, Bioeurope, Biospain, AIS), and inbound inquiries via the company website. Customer segments are horizontal across two tiers: emerging biotech startups needing flexible end-to-end services from cell line development through clinical manufacturing, and established pharmaceutical companies requiring additional capacity or specialized platform access. The company reports having guided 100+ molecules from proof of concept to advanced clinical stages and holds strategic agreements with major global multinational pharmaceutical firms.

The business is in a transformative capacity-buildout phase. A €20 million investment announced in December 2023 is funding a 3,500m² GMP biologics plant in Sant Quirze del Vallès, Barcelona, with three production lines for mammalian, microbial, and gene therapy molecules — selected as a Vanguard Health PERTE initiative. The facility is scheduled to come online in Q4 2025, with CMO (Contract Manufacturing Organization) activities launching in Q2 2026, which will transition Leanbio from a development-services CDMO to one with recurring commercial manufacturing revenue. Leanbio is privately held by co-founders Andreu Soldevila Fàbrega and Albert Font, with no disclosed institutional investors; non-dilutive funding has come via a €688,224.60 CDTI grant (under EU NextGenerationEU) for an mRNA-based influenza vaccine program running through March 2025.

Name

Leanbio

Legal name

Leanbio S.L.

Website

https://leanbiopro.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Leanbio is a Barcelona-based CDMO founded in 2014 that provides end-to-end development and manufacturing services for biopharmaceuticals across mammalian, microbial, mRNA, pDNA, and bioconjugate platforms, serving biotech startups and global pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Biopharmaceutical CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP) (HLAGAGAG)

Keywords

• Biologics contract manufacturing
• Biopharmaceutical CDMO services
• Mammalian cell expression
• Microbial fermentation services
• MRNA manufacturing services

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. CDMO Development Services: Leanbio generates revenue through providing contract development and manufacturing services for biopharmaceutical products. Services include tech transfer, cell line development, process development, analytical development, preclinical manufacturing, cell banking, process validation, and cGMP manufacturing. Revenue is project-based, typically structured as milestone payments throughout the development and manufacturing lifecycle.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Leanbio is a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end development and manufacturing services for biologics. Its portfolio spans five technological offerings (Mammalian, Microbial, pDNA, mRNA, Bioconjugates) supported by eight service modules (Tech Transfer, Cell Line Development, Process Development, Analytical Development, Preclinical Manufacturing, Cell Banking, Process Validation, cGMP Manufacturing). The company supports biotech startups and pharmaceutical companies in bringing New Biological Entities and Biosimilars from proof of concept through clinical stages.

Product overview

Leanbio is a global CDMO (Contract Development and Manufacturing Organization) offering integrated development and manufacturing services for biopharmaceutical products. The company provides a unified platform spanning five technological offerings: Mammalian Expression Platform, Microbial Expression Platform, pDNA Manufacturing, mRNA Manufacturing, and Bioconjugates (ADC/PDC). These platforms are supported by eight complementary service modules including Tech Transfer, Cell Line Development, Process Development, Analytical Development, Preclinical Manufacturing, Cell Banking, Process Validation, and cGMP Manufacturing. The portfolio enables end-to-end support from early-stage development through commercial production, covering expression systems (CHO, HEK, E.coli, Pichia pastoris), recombinant proteins, antibodies, mAbs, bispecifics, fusion proteins, enzymes, hormones, peptides, and advanced therapies (mRNA, gene therapy, ADCs).

Differentiator

Problem solved

Functional benefit

Products and services

• Mammalian Expression Platform Expression platform utilizing CHO (Chinese Hamster Ovary) and HEK (Human Embryonic Kidney) cells for production of antibodies, fusion proteins, and other biologics. Supports scales from 3L to 2,000L bioreactors with batch, fed-batch, and perfusion modes using single-use bioreactors.
• Microbial Expression Platform Expression platform using E.coli, Pichia pastoris, and Bacillus subtilis for recombinant protein production. Supports scalable manufacturing from 3L to 1,000L bioreactors with capabilities for soluble and insoluble protein fractions including advanced refolding methodologies.
• pDNA (Plasmid DNA) Manufacturing End-to-end plasmid DNA manufacturing for gene therapies, vaccines, and mRNA therapeutics. Includes high-yield fermentation and multiple chromatographic purification steps for scales from bench to 1,000L.
• mRNA Manufacturing Comprehensive mRNA production from plasmid DNA template generation through in vitro transcription (IVT) to purification and formulation. Supports scales from bench to 50L for preclinical, clinical, and commercial applications under cGMP conditions.
• Bioconjugates (ADC/PDC) Specialized manufacturing of antibody-drug conjugates (ADCs) and protein-drug conjugates (PDCs). Includes controlled bioconjugation for precise drug-to-antibody ratios (DAR), scalable processes, and cGMP batch manufacturing with both cleavable and non-cleavable linkers.
• Tech Transfer Project evaluation and transfer services designed to reduce risks, streamline processes, and accelerate timelines. Includes support at any project stage, dedicated experts, customized assessment, and cross-functional integrated support.
• Cell Line Development Cell line development services for mammalian systems (CHO, HEK) and microbial systems (E.coli, Pichia pastoris, Saccharomyces cerevisiae, Bacillus spp.). Features robust single-cell clone selection and lean selection methods to reduce time and cost.
• Process Development Process development for upstream and downstream biologics production. Includes media composition optimization, cell culture conditions, purification methods, analytical method development, and formulation development. Specializes in complex molecules including bispecific antibodies, fusion proteins, and ADCs.
• Analytical Development Comprehensive analytical solutions including CQA identification, protein characterization (sequence confirmation, glycan profiling, PTMs analysis), mRNA/pDNA characterization, purity/impurity profiling, potency bioassays, and residual impurity testing. Uses chromatography, mass spectrometry, and other advanced techniques.
• Preclinical Manufacturing Early-stage biologics manufacturing for preclinical research including pharmacology and toxicology studies. Supports scalable production from bench-scale (mL) to pilot-scale (100L) and large volumes up to 2,000L. Includes customizable non-GMP production and bioconjugation services.
• Cell Banking GMP-compliant cell banking services including production of Master Cell Banks (MCB) and Working Cell Banks (WCB), comprehensive characterization and QA testing, secure temperature-monitored storage, and ongoing cell bank stability studies.
• Process Validation Process validation services ensuring biopharmaceutical manufacturing meets quality, safety, and compliance standards. Includes risk assessments, analytical methods validation, process characterization (CPPs/CQAs), process validation, Process Performance Qualification (PPQ), and continuous process validation.
• cGMP Manufacturing End-to-end cGMP manufacturing services for biologics including antibodies, fusion proteins, glycosylated proteins, and therapeutic enzymes. Supports scales up to 1,000L microbial and 2,000L mammalian production with full regulatory compliance to EMA and FDA standards.

Quantifiable outcome

• 100+ molecules successfully guided from proof of concept to advanced clinical stages
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• WuXi Biologics: Global biologics CDMO offering end-to-end discovery, development, and manufacturing services across mammalian and microbial platforms. Competes with Leanbio for biotech outsourcing contracts, especially among European and US biotechs.
• Lonza Group: Global CDMO leader with large-scale mammalian and microbial biologics manufacturing across multiple sites. Comparable as a multi-modality biologics CDMO serving biotech and Big Pharma, though at significantly greater scale and geographic reach than Leanbio.
• Samsung Biologics: Large-scale biologics CDMO offering mammalian cell culture, fill-finish, and biosimilars manufacturing. Operates mega-plants (100,000L+ bioreactors) targeting the same biotech and pharma customer base as Leanbio but at a fundamentally different scale tier.
• Boehringer Ingelheim BioXcellence: Biologics CDMO division of Boehringer Ingelheim offering mammalian cell culture, microbial, and cell therapy manufacturing at commercial scale. Competes for similar biotech and pharma outsourcing contracts.

Direct peers

• Celonic Group: European CDMO (Germany/Switzerland) offering mammalian and microbial biologics development and GMP manufacturing, including cell line development and process development. Comparable mid-sized peer with similar platform and European positioning.
• Biovian: Finnish CDMO specializing in microbial (E. coli, Pichia) biologics, pDNA, and AAV/gene therapy manufacturing. Comparable as a European mid-sized CDMO with overlapping microbial and nucleic acid capabilities.
• Rentschler Biopharma: European-headquartered (Germany) CDMO specializing in mammalian cell culture biologics from cell line development through commercial manufacturing. Directly comparable European mid-sized CDMO serving biotech and pharma clients.
• Northway Biotech: European CDMO offering microbial and mammalian biologics development and GMP manufacturing. Comparable mid-sized peer serving biotech startups with integrated development and manufacturing services.
• AGC Biologics: Mid-to-large tier CDMO offering mammalian and microbial biologics, cell and gene therapy, and mRNA/pDNA services. Closely comparable to Leanbio in platform breadth and customer mix, though with substantially greater commercial-scale capacity.
• Abzena: CDMO offering biologics development, manufacturing, and bioconjugation services including ADCs. Directly comparable for Leanbio's bioconjugate and complex biologics offerings, particularly for ADC development and manufacturing.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/leanbiopro

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leanbio